Leading synthetic biologists have shared hard-won lessons from their decade-long quest to build the world's first synthetic ...
A cutting-edge therapy using base-edited immune cells is offering a major breakthrough for patients with one of the toughest ...
Rezolute shares plunged 90% in premarket trading after its Phase 3 trial for ersodetug failed to show meaningful benefit in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback